Sangamo Therapeutics, Inc.

NASDAQ:SGMO

Biotechnology

Healthcare
$0.18 +2.06%

+$0.00 today

Market cap
$70.43M
Beta
1.29
P/E (TTM)
-0.5
EPS (TTM)
-$0.32
52W Low $0.10High $0.77

Volume 0.61M

Average 9.53M

SGMO Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Sangamo Therapeutics, Inc.NASDAQ: SGMO

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin holds steady near 100.0%

Gross margin was 100.0% in Q1 FY2026, up 0.0 pp from a year earlier. On a trailing-twelve-month basis it was 100.0%, up 0.0 pp year over year. Over 3 fiscal years it narrowed by 8.3 pp.

Context

  • Gross margin widened in 1 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
100.0%+0.0 pp QoQ
Last fiscal yearDec 2025
80.8%-19.2 pp YoY
LTMMar 2026
100.0%+0.0 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+0.0 pp——
1 year-19.2 pp——
3 years-8.3 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
80.8%
Year-over-year change
-19.2pp

Gross Margin vs competitors

How SGMO compares with its peers on the latest reported figures

  • SGMO's LTM Mar 2026 gross margin of 100.0% is the highest of the 10 companies compared; the peer median is 92.0%.
  • Its year-over-year change of +0.0 pp is the 4th highest of 9, against a peer median of -0.6 pp.
  • Over three fiscal years its change of -8.3 pp compares with a peer median of +6.6 pp.
SGMO Competitors Peer median
Gross Margin for SGMO and competitors
Company Period LTM level YoY 3-year change
SGMOSangamo Therapeutics, Inc.LTM Mar 2026100.0% +0.0 pp-8.3 pp
IPHAInnate Pharma S.A.FY2025100.0% +0.0 pp+89.6 pp
RANIRani Therapeutics Holdings, Inc.LTM Mar 202694.9% -5.1 pp—
CCCCC4 Therapeutics, Inc.LTM Mar 202694.8% +9.6 pp-22.2 pp
MISTMilestone Pharmaceuticals Inc.LTM Mar 202694.7% —-7.4 pp
IVVDInvivyd, Inc.LTM Mar 202692.0% -1.3 pp—
CDXSCodexis, Inc.LTM Mar 202683.9% +12.4 pp+14.2 pp
ARMPArmata Pharmaceuticals, Inc.LTM Mar 202672.2% +1.7 pp+604.5 pp
OABIOmniAb, Inc.LTM Mar 202635.5% -64.5 pp-118.2 pp
IMDXInsight Molecular Diagnostics Inc.LTM Mar 202619.5% -33.1 pp+6.6 pp
MOLNMolecular Partners AGFY2025— ——
Peer median (excluding SGMO) 92.0%-0.6 pp+6.6 pp

Competitors are the stored peer set for SGMO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue110.7M111.3M176.23M57.8M39.55M
Cost of Revenue012.11M007.6M
Gross Profit110.7M99.19M176.23M57.8M31.95M
Gross Margin100.0%89.1%100.0%100.0%80.8%
Research & Development230.82M249.9M234.06M111.52M112.67M
Selling, General & Admin63.22M62.68M61.17M44.73M34.89M
Operating Expenses294.04M300.47M450.24M161.77M139.95M
Depreciation & Amortization17.64M12.11M22.19M9.36M7.6M
EBITDA(160.35M)(179.74M)(96.8M)(89.09M)(115.9M)
EBITDA Margin-144.9%-161.5%-54.9%-154.1%-293.0%
Operating Income(183.34M)(201.28M)(274.01M)(103.97M)(108M)
Operating Margin-165.6%-180.8%-155.5%-179.9%-273.1%
Interest Income5.35M9.43M11.1M5.86M1.3M
Interest Expense00000
Other Income / Expenses5.35M9.43M11.1M5.86M(15.5M)
Income Before Tax(177.99M)(191.85M)(262.9M)(98.11M)(123.5M)
Pre-Tax Margin-160.8%-172.4%-149.2%-169.7%-312.2%
Income Tax Expense306K429K(5.07M)(167K)(568K)
Net Income(178.29M)(192.28M)(257.83M)(97.94M)(122.93M)
Net Margin-161.1%-172.8%-146.3%-169.4%-310.8%
EPS (Basic)(1.23)(1.25)(1.48)(0.49)(0.44)
EPS (Diluted)(1.23)(1.25)(1.48)(0.49)(0.44)
Weighted Avg Shares144.57M154.35M174.44M201.7M280.19M
Weighted Avg Shares (Diluted)144.57M154.35M174.44M201.7M280.19M

Sangamo Therapeutics, Inc.

NASDAQ:SGMO

Intrinsic Alpha fair value

Locked

Current Price

$0.18

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.